2015年5月
Pediatric Rheumatology Association of Japan recommendation for vaccination in pediatric rheumatic diseases
MODERN RHEUMATOLOGY
- ,
- ,
- ,
- ,
- ,
- ,
- ,
- ,
- ,
- 巻
- 25
- 号
- 3
- 開始ページ
- 335
- 終了ページ
- 343
- 記述言語
- 英語
- 掲載種別
- DOI
- 10.3109/14397595.2014.969916
- 出版者・発行元
- SPRINGER
Pediatric Rheumatology Association of Japan has developed evidence-based guideline of vaccination in pediatric rheumatic diseases (PRDs) as a part of Guideline of Vaccination for Pediatric Immunocompromised Hosts. Available articles on vaccination in both adult rheumatic diseases and PRDs were analyzed. Non-live vaccines are generally safe and effective in patients with PRDs on corticosteroid, immunosuppressant, and/or biologics, although efficacy may be attenuated under high dose of the drugs. On the other hand, efficacy and safety of live-attenuated vaccine for the patients on such medication have not been established. Thus, live-attenuated vaccines should be withheld and, if indicated, may be considered as a clinical trial under the approval by Institutional Review Board. All patients with PRDs anticipating treatment with immunosuppressants or biologics should be screened for infection of hepatitis B and C and tuberculosis before the commencement of medication. Varicella vaccine should be considered in sensitive patients ideally 3 weeks or longer before the commencement of immunosuppressants, corticosteroids, or biologics. Bacille Calmette-Guerin should be withheld at least for 6 months after birth, if their mothers have received anti-tumor necrosis factor-alpha antibodies during the second or third trimester of pregnancy
- リンク情報
- ID情報
-
- DOI : 10.3109/14397595.2014.969916
- ISSN : 1439-7595
- eISSN : 1439-7609
- PubMed ID : 25381726
- Web of Science ID : WOS:000353772900001